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Abstract
Toll-like Receptor 3 (TLR3) is a pathogen pattern recognition receptor that plays a key role in innate immunity. TLR3
signalling has numerous functions in liver, both in health and disease. Here we report that TLR3 is expressed by quiescent
hepatic stellate cells (HSC) where it functions to induce transcription and secretion of functional interferons as well as a
number of other cytokines and chemokines. Upon transdifferentiation into myofibroblasts, HSCs rapidly loose the ability to
produce interferon gamma (IFNc). Mechanistically, this gene silencing may be due to Polycomb complex mediated
repression via methylation of histone H3 lysine 27. In contrast to wild type, quiescent HSC isolated from tlr3 knockout mice
do not produce IFNc in response to Poly(I:C) treatment. Therefore, quiescent HSC may contribute to induction of the
hepatic innate immune system in response to injury or infection.
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Introduction
Hepatic stellate cells (HSC) are specialised pericytes of the liver
sinusoids found in the Space of Disse`, a basement membrane-like
structure located between columns of hepatocytes and sinusoidal
endothelial cells [1]. The most characterised function of HSCs is
the ability to transdifferentiate from a quiescent phenotype into
highly proliferative, contractile and wound-healing myofibroblast
[2]. This so-called activated HSC (aHSC) produces vast quantities
of fibril-forming collagens and promotes net deposition of fibrotic
extracellular matrix, a process important for repair following
infection or trauma to the liver. However, in the chronically
injured liver, this normal physiological process may become
dysregulated and lead to the development of fibrosis [1].
The role of quiescent HSCs (qHSC) has received much less
attention. A known key function is storage of Vitamin A which is
found in numerous intracellular droplets [3,4]. Additionally,
several investigators have described that qHSC possess multiple
thorn-like cytoplasmic extensions which can protrude into the
sinusoidal space or make direct contact with hepatocytes. These
membrane projections have been shown to function as a leading
edge for the qHSC and play a role in sensing of extracellular
factors that influence HSC phenotype. Given the anatomical
location of qHSCs and their morphology, they have the potential
to operate as sinusoidal sentinels, detecting mechanical or
biochemical alterations in hepatocytes, endothelial cells, within
the Space of Disse` or even within the sinusoidal spaces [4].
The innate immune system serves as a ‘‘first defence’’
responding to acute tissue trauma or infection by mounting
protective anti-microbial and wound-healing response. These
responses are mediated by a variety of immune cells including
recruited neutrophils, mast cells, eosinophils, natural killer (NK)
cells and tissue macrophages. The molecular triggers for innate
immunity are pattern recognition receptors (PRRs) [5] including
the IL-1 Receptors [6] (reviewed in [7]), members of the Toll-like
Receptor (TLR) family [8] and Nucleotide Oligomerisation
Domain (NOD)-like receptor families [9]. A total of 13 distinct
mammalian TLRs (TLR1-13) have been identified to date and
each responds to specific ligands of microbial origin or from the
intracellular contents of damaged or dying host cells. Upon
engagement by their ligands, the TLRs trigger a cascade of
intracellular signalling pathways that culminate in induction of
genes encoding interferons, cytokines and chemokines required for
the recruitment and activation of innate immune cells [10].
Activated human HSCs express TLR4 and are able to respond
to its ligand lipopolysaccharide (LPS) with activation of IKK/NF-
kB and subsequent expression of a variety of pro-inflammatory
cytokines [11]. Mouse HSCs are reported to express TLR2, 4 and
9 and are responsive to their respective ligands which induce the
secretion of IL-6, TGFb1 and MCP1 [12–14]. Recent studies by
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e83391
Seki et al, have described how TLR4 on activated mouse HSC is
required for sensitising the cells to TGFb1, specifically by
promoting down-regulation of the TGFb1 pseudo-receptor Bambi
[13]. The observation that mice lacking TLR4 or its downstream
adaptor Myd88 were resistant to fibrosis induced by a variety of
different injury mechanisms highlighted the importance of innate
immune receptor in hepatic wound-healing response.
In the present study, we have addressed the question of which
TLRs are expressed and functional on qHSC. We focused on
TLR3, a sensor of dsRNA, which is expressed at relatively high
levels on both qHSC and aHSC but has distinct functions in these
two phenotypic states. Our data suggest that engagement of TLR3
on qHSC results in induction of interferons (a,b and c) and
cytokine (IL-6) gene expression. However, aHSC lose the capacity
to induce interferons in response to TLR3, but retain TLR3-
induction of IL-6. Our data suggest that qHSC may play a
significant contributing role to TLR3-mediated interferon-depen-
dent innate immune responses.
Materials and Methods
Ethics statement
All animal experiments were undertaken in accordance with
appropriate licences for animal experiments which were issued/
approved by local ethical committee and UK Home Office.
Animals and models of liver disease
Chronic CCl4 liver injury model. Fibrogenesis was induced
by 4-week CCl4 treatment of 250 g adult Sprague-Dawley rats.
Rats were injected intraperitoneally (IP) twice weekly with CCl4/
olive oil mix in a 1:3vol/vol ratio at 2 ml/g body weight. Twenty-
four hours after the final CCl4 administration, animals were
sacrificed and blood and tissues harvested.
Acute CCl4 liver injury. Single dose of CCl4 was given by IP
injection prepared as CCl4/olive oil in a 1:1vol/vol ratio at 2 ml/g
body weight to both rats and mice. Animals were sacrificed at
varying times after injury (as stated in figures and figure legends)
and tissues harvested for histological and molecular analysis.
SDS-PAGE and Immunoblotting
SDS-PAGE and immunoblotting was performed as previously
described [15]. Primary antibodies recognising TLR3 (AnaSpec),
IRAK1, TRAF6 (Santa Cruz) were used at 1:1000 dilution and
GAPDH (Abcam) at 1:2000. Membranes were probed with the
appropriate secondary antibody (anti-mouse Sigma; anti-rabbit
Cell Signalling Technologies) and proteins visualised using
chemiluminescence (Pierce).
Immunocytochemistry
Formalin fixed, paraffin embedded tissue was dewaxed and
rehydrated in decreasing concentrations of ethanol. Sections
underwent antigen retrieval in citric saline solution and were
subsequently permeabilized with 0.1% saponin in 0.5% bovine
serum albumin (BSA). Toll-like receptor 3 primary antibody
(AnaSpec) was used in a concentration of 1:1000 and incubated at
room temperature for 1 hour. Coverslips were mounted in DAPI-
containing fluorescent mounting media.
Quantitative Reverse Transcriptase-Polymerase Chain
Reaction (qRT-PCR)
Total RNA was purified from isolated cells or whole liver using
the RNeasy Mini Kit (Qiagen, UK). cDNA was generated using
random hexamer primers and MMLV reverse transcriptase
enzyme (Promega, UK). Quantitative PCR was performed on
an ABI 7500 with a 3 step amplification program: 20 sec at 94uC,
40 cycles of 20 sec at 55uC, 30 sec at 72uC and 5 sec at 94uC. All
reactions were normalised to GAPDH and relative level of
transcriptional difference calculated using the following equation:
1/(2A)6100. (Primer sequences are listed in Table 1).
Reagents
TLR ligands. Rat and mouse HSCs were incubated with
TLR ligands (InvivoGen) as detailed in figure legends. The ligands
and their concentration in cell culture were (unless otherwise
stated) - TLR2 (Lipoteichoic (LTA), 100 ng/ml), TLR3 (Poly
(I:C), 1 mg/ml), TLR4 (lipopolysaccharide (LPS), 100 ng/ml),
TLR5 (flagellin, 1 mg/ml), TLR7/8 (Imiquimod, 1 mg/ml) and
TLR9 (stimulatory CpG ODN, 10 mg/ml). IL-1a was used at a
concentration of 2 ng/ml (Peptroech 211-11A), IFNc at 100 ng/
ml (Peprotech 315-05). Transcriptional inhibitors, actinomycin D
and 5,6-Dichlorobenzimidazole Riboside (DRB) were purchased
from Sigma Aldrich (A9415 and D1916 respectively). The C13-
GT was used at a concentration of 20 mg/gram of body weight.
Clodronate-liposomes were a kind gift from Professor Mirco
Ponzoni and injected intraperitoneally at a concentration of
25 mg/gram of body weight.
Table 1. Table of primers.
Species Gene Forward Reverse
Rat Collagen ttcacctacagcacgcttgtg gatgactgtcttgccccaagt
Rat b-actin agccatgtacgtagcccatcc ctccagctgtggtggtgaa
Rat a-SMA cgaagcgcagagcaagaga catgtcgtcccagttggtgat
Rat IL-1b ttcaaatctcacagcagcat catcccacgagtcacagagg
Rat IL-6 acaagataacaagaaagacaaa Agtcttttatctcttgtttga
Rat Interferon a ggctcggctctgtgctttct atttgtgccaggagtgtgaa
Rat Interferon b actgggtggaatgagactat taaagtagtcgtggatgtca
Rat Interferon c ggatgctatggaaggaaaga gcgattcgatgacacttatg
Rat CCL2/MCP1 ggaccagaaccaagtgagatc gaggtggttgtggaaaagaga
Rat CCL5/RANTES catccctcaccgtcatcctc tctgggttggcacacacttg
Rat TNF-a gccaccacgctcttctgtct cctctgcttggtggtttgctac
Rat MxA actccatcctgcaaacatttgggc accagttgcacttactggtgtcct
Rat TIMP1 gcaactcggacctggtcataa cggcccgtgatgagaaact
Rat TLR1 tccagtatcttaatatcagtg catataggcagggcatcaaa
Rat TLR2 tgtcagtggccagaaaagatg agattgttgttactaacatc
Rat TLR3 agccttcaacgactgatgct atttctagattctcaagacc
Rat TLR4 gtaaagaatttagaagaagg gagcaatctcatattcaaag
Rat TLR5 cctgctcagcttcaactata ctaagattgggcaggtttct
Rat TLR6 taatattaaattgaatgatga gttaagttgtaaatattgag
Rat TLR7 aaaactgttattatcgaaat gctgtgacattgttatct
Rat TLR8 tagaggagagggattggg tcatccattagcctctgcaa
Rat TLR9 tcaatggctctcagttcctg aagggctggctgttgtagct
Rat TLR10 tggcaagagccagtttgt cccagagcaggtcaactttat
Rat TLR11 cctttcctcctacatcccattc cctctgtatttctgggcactt
Rat TLR12 ctgtgtctactctgcttcc aaggcatcaggaggtaga
Rat TLR13 - like cagaggccattagtgacatacc ccagagcagacagattagtgaaa
doi:10.1371/journal.pone.0083391.t001
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tlr2/23 knockout mice
The knockout mice were obtained from Dr Lars Eckmann,
University of Southern California, San Diego, USA. Authors wish
to thank Dr Eckmann for his help and support with breeding and
supplying the mice. The knockout mice were originally generated
as described in [16].
Hepatic Stellate Cell isolation
Rat and mouse HSCs were isolated from 250 g male Sprague-
Dawley rats and 25–30 g adult male mice respectively, by
sequential perfusion with collagenase B (Roche) and pronase
(Roche) and quiescent HSCs separated by discontinuous density
centrifugation in 11.5% Optiprep (Sigma Aldrich D1556). Mouse
and rat primary HSCs were maintained at 37uC (5% CO2) in
Dulbecco’s Modified Eagle’s Media supplemented with 16% foetal
bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomy-
cin, 2 mM L-glutamine (Life Technologies). Culturing of freshly
isolated quiescent HSC on tissue culture plastic leads to their
activation over a period of 7 to 10 days and spontaneous
acquisition of a myofibroblast phenotype, which is thought to be
highly representative of in vivo HSC activation.
Murine Macrophage isolation
Bone marrow cells were isolated from the femurs of C57/Blk6
mice as previously described [17]. Briefly, cells were differentiated
into macrophages by culturing for 7 days with media supplement-
ed with 5% horse serum (Sigma Aldrich H1270) and 10% of L929
cell line conditioned media (that contains M-CSF).
Enzyme linked Immunosorbent Assay
Culture supernatant concentration of IL-6 was measured using
a rat IL-6 Quantikine ELISA according to manufacturer’s
instructions (R&D Systems Minneapolis, MN).
Fluorescence activated cell sorting (FACS)
Cells were incubated at 4uC for 1 hr with 24G2 antibody that
prevents non-specific Fc receptor binding, followed by 1 hr
incubation at 4uC with anti MHC class II-FITC conjugated
antibody (eBioscience 11-0920-82). Following incubation, cells
were washed and resuspended in 2% FBS in phosphate-buffered
saline. Up to 10,000 events were analysed on FACScan/FACS
Canto II (BD, Oxford, UK) using Flowjo software (FlowJo, Inc).
Chromatin Immunoprecipitation Assay
Antibodies used for immunoprecipitation were purchased from:
histone H3 di methyl K27 (H3K27me2, Abcam) and Histone H3
trimethyl K27 (H3K27me3, Diagenode). 10 mg of each antibody
or appropriate irrelevant antibody control were used in each ChIP
reaction as described previously [18]. Primers used for detection of
relevant rat genomic sequences were: IFNc 243 kb sense 59-
aaggtcaagccataacattc-39 and antisense 59- cagggatgaacaaggaccag-
39; IFNc 20.5 kb sense 59- cttttgtaaccgaacgccttc-39 and antisense
59- cttttacttcacaccatttg-39; IFNc 0.4 kb sense 59- tcggtgaggtgttcgtt-
gac-39 and antisense 59- aagaatgaaaaccatgaagg-39 and IFNc
1.1 kb sense 59- gagttgagtttatttgtgg-39 and antisense 59-
ctgtggagttttgttgaatg-39. Each PCR reaction was performed in
triplicate and the analysis was repeated three times from
independent ChIP experiments. A signal intensity value for each
sample was calculated from the average of the experiments.
Average values of eluates were normalized to average values of
control antibody sample and expressed as fold enrichment above
background (i.e. control antibody) [18].
Statistical Analysis
Data are expressed as means 6 standard error of the mean
(SEM). All P values were calculated using a two-tailed paired or
unpaired Student t test. Statistically significant data is represented
in figures where *, **, and *** denote P values of ,0.05, ,0.01
and ,0.001, respectively.
Results
TLR3 is expressed and functional in quiescent and
activated HSC
To determine relative expression of TLRs between qHSC and
aHSC we measured transcript expression for TLR1-13 in freshly
isolated or culture-activated rat HSC. TLR2, 3, 7, 8 and 13
transcripts were all induced with culture activation and were
expressed at relatively high levels compared with other TLRs
(Figure 1A). The highest expressed TLR transcripts in qHSC were
TLR3 (27.57615.16 RLTD) and TLR13 (14.5468.09 RLTD)
(p,0.05 compared with other TLR transcripts). Western blot
analysis confirmed that TLR3 protein is expressed in both qHSC
and aHSC, however no significant change in expression occurred
with activation (Figure 1B). Furthermore, we confirmed presence
of TLR3 in qHSC (culture day 1) by immunocytochemistry
(Figure 1C). As no previous studies have reported a role for TLR3
in qHSC we determined if they are responsive to the TLR3 ligand
Poly(I:C). As illustrated in Figure 1D, qHSCs treated with
Poly(I:C) underwent a transient increase in IL-6 mRNA transcript
that peaked between 2 (9.7 RLTD, p,0.001) and 4 (10.54 RLTD,
p,0.001) hours following treatment (Figure 1D). By contrast
qHSC were unresponsive to IL-1a (Figure 1D) which may be
explained by absence of key downstream signalling factors TRAF6
and IRAK1 in quiescent HSC, which are subsequently induced
during HSC activation (Figure 1E). As expected, aHSC were fully
responsive to IL-1a treatment which stimulated the expression of
IL-6 and TIMP-1 indicating a profibrogenic phenotype
(Figure 1F). Maximal induction of IL-6 and TIMP-1 occurred
after 8 hours of IL-1a treatment (7.6961.14 RLTD, 4.360.62
RLTD, respectively p,0.001)
We next determined the function of TLR3 alongside other
TLRs in aHSC. Culture-activated rat HSCs were exposed
between 0 and 24 hours to TLR2 (LTA), TLR3 (Poly(I:C)),
TLR4 (LPS), TLR5 (flagellin) or TLR7 (imiquimod) agonists.
Measurement of IL-6 mRNA expression revealed a strong
induction upon activation of TLR3 with Poly(I:C) (9.0661.41
RLTD, p=0.001) and TLR4 with LPS (7.8263.3 RLTD,
p= 0.056) which peaked at 5 and 4 hours, respectively. Weaker
responses were found in response to engagement of TLR2 (LTA)
(4.3161.6 p= 0.1), TLR5 (flagellin) and TLR7 (imiquimod) (data
not shown) both peaking earlier at 2 hours (Figure 2A). Addition-
ally, we monitored IL-6 secretion from aHSC in response to the
same TLR agonists over a 24 hr period by ELISA (Figure 2B).
LTA, LPS and imiquimod treatment was associated with a
minimal 4-fold increase in secreted IL-6 at 24 hours
(36226215 pg/ml, p,0.001; 3790664 pg/ml, p,0.001; respec-
tively, imiquimod data not shown). Poly(I:C) treatment resulted in
a 5-fold increase in secreted IL-6 by 8 hours (51506170 pg/ml,
p,0.001) further increasing to a 7-fold induction by 24 hours
(7480628 ng/ml, p,0.001)). We saw no increase in secreted IL-6
with Flagellin treatment, confirming lack of response of aHSC to
TLR5 signalling, at least in terms of IL-6 secretion (Figure 2B). We
conclude that qHSC and aHSC are able to mount inflammatory
cytokine responses following engagement of TLR3. However,
Poly(I:C) treatment failed to induce significantly higher levels of
TIMP-1, Collagen I or a-SMA transcripts (Figure 2C), suggesting
Role of TLR3 in Quiescent Hepatic Stellate Cells
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that it is unlikely that TLR3 functions as a modulator of the
fibrogenic activities of HSCs.
Activation of HSC decreases TLR3-mediated interferon
response and subsequent cytokine production
TLR3 plays a fundamental anti-viral role by producing
interferons (IFN) in response to viral dsRNA [19]. Given that
HSC express functional TLR3, we were intrigued to determine if
the activation of the receptor can trigger IFN production in these
cells. For this purpose we isolated HSC from 3 groups of rats;
control group which was given olive oil vehicle (qHSC); rats
administered CCl4 acutely for 48 hours (transitionary HSC) and
rats receiving a chronic CCl4 injury for 4 weeks (myofibroblastic
aHSC). HSC were subsequently treated for up to 24 hours with
Poly(I:C) prior to measurement of gene expression by qRT-PCR.
Figure 1. Quiescent and activated HSCs express Toll like receptors. (A) mRNA levels of TLR1-13 were quantified by qRT-PCR in three separate
preparations of primary rat qHSCs (day 0) and day 10 transdifferentiated myofibroblasts. Data are expressed as relative level of transcriptional
difference (RLTD) to TLR1 mRNA expression (n = 3). (B) Thirty micrograms of whole cell protein extract from three separate preparations of quiescent
rat HSCs (culture day 1) or activated myofibroblasts (culture day 10) were separated by SDS-PAGE and immunoblotted for TLR3 and GAPDH. (C) Toll-
like receptor 3 was visualised in the cytoplasm of rat qHSCs (ex vivo) culture day 1 (bar represents 75 mm). (D) Quiescent rat HSCs were treated with
Poly(I:C) (1 mg/ml) or IL-1a (2 ng/ml) for up to 24 hours; IL-6 mRNA was measured and normalised to b actin (n = 3). (E) Thirty micrograms of whole
cell protein extract from two separate preparations of quiescent HSCs or activated myofibroblasts (culture day 10) were separated by SDS-PAGE and
immunoblotted for IRAK1, TRAF6 and GAPDH. (F) Activated rat myofibroblasts were treated with IL-1a (2 ng/ml) for up to 24 hours; IL-6 and TIMP1
mRNA were measured and normalised to b actin (n = 3). (*p,0.05, ***p,0.001).
doi:10.1371/journal.pone.0083391.g001
Role of TLR3 in Quiescent Hepatic Stellate Cells
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Figure 2. Hepatic stellate cells are responsive to stimulation by TLR ligands. (A) mRNA level of IL-6 was quantified by qRT-PCR in four
separate preparations of activated rat HSCs (culture day 10) treated with TLR2 ligand (LTA, 100 ng/ml), TLR3 ligand (Poly(I:C), 1 mg/ml), TLR4 ligand
(LPS, 100 ng/ml) or TLR5 ligand (Flagellin, 1 mg/ml) for up to 24 hours (n = 4). Expression level was normalised to b actin. (B) Secreted IL-6 protein was
measured by ELISA in conditioned media collected from activated HSCs treated with TLR ligands as in (A) following 2 h, 8 h or 24 h of stimulation
(n = 4). (C) mRNA levels of IL-6, TIMP1, aSMA and collagen I were quantified by qRT-PCR in four separate preparations of activated rat HSCs (culture
day 10) treated with TLR3 ligand (Poly(I:C), 1 mg/ml) for up to 24 hours. Expression level was normalised to b actin. (#p,0.1, *p,0.05,
**p,0.01***p,0.001).
doi:10.1371/journal.pone.0083391.g002
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HSC from untreated rats responded to Poly(I:C) with induction of
transcripts for IFNa, b and c (Figure 3A–C). However, HSC
isolated from acute and chronic CCl4-injured animals failed to
induce IFN gene expression to similar levels seen in quiescent
HSCs (Figure 3A–C). Additionally, we see failure of induction of
key cytokines CXCL10, TNF-a, MxA, CXCL1/KC and IL-1b in
transitionary and activated HSCs compared with quiescent HSCs
(Figure 3D). Similar to Wang and colleagues, we also found
indoleamine 2,3-dioxygenase was induced after stimulation of
qHSCs with Poly(I:C) [20], and this was subsequently reduced in
transitionary and activated HSCs (Figure 3D). However, these
findings were not universal and we found no change in induction
of cytokines such as CTGF, IL-10, MCP1 and CCL5 (Figure S1).
In all studies, HSC were pre-plated in order to remove
contaminating Kupffer cells (KC), however it remained possible
any remaining minor contamination with KC was responsible for
the observed TLR3 induction of IFN gene expression. To address
this issue, HSC were isolated from rats treated with clodronate-
liposomes for 48 hours to clear KC from the liver. Isolated qHSC
from clodronate-treated rats were then exposed to Poly(I:C) for 2,
8 and 24 hours prior to measurement of secreted IFNc in the
culture media. Media from control qHSC contained low levels of
IFNc, by contrast media from qHSC treated for 8 or 24 hours
with Poly(I:C) contained greater than 100 pg/ml levels of IFNc
(p,0.01 for both 8 and 24 hours)(Figure 3E). As a control for
these experiments we also determined IFNc production by qHSC
isolated from rats administered carrier liposomes only (Figure 3F),
these cells responded to Poly(I:C) by producing only slightly higher
levels of IFNc than qHSC from rats exposed to clodronate-
liposomes. Hence any KC contaminant in the qHSC cultures
makes only a minor contribution to the overall level of TLR3-
induced IFNc in the culture model. To confirm that qHSC
produce bioactive IFNc capable of modulating immune responses,
macrophages were exposed to media conditioned by qHSC
exposed to Poly(I:C) for 8 hours and induction of MHC class II
was measured by FACS. Macrophage class II expression was
increased in media from Poly(I:C) treated qHSC compared with
untreated media, though levels remain less than in macrophages
Figure 3. Activation of HSC decreases TLR3 mediated interferon and cytokine response. (A,B,C) HSCs were isolated from control, acute
CCl4 treated rats (single injection), or chronic CCl4 treated rats (4 weeks twice weekly injections); cells were seeded onto plates and treated with
Poly(I:C) (1 mg/ml) for up to 24 hours. Interferon a, b and c were measured and normalised to b actin. Data are expressed as RLTD. (D) Interferon-
inducible cytokines CXCL10, TNF-a, MxA, CXCL1/KC, IL-1b and indoleamine 2,3-dioxygenase were measured and normalised to b actin (n = 4). Data
are presented as fold change, Poly(I:C) stimulated to unstimulated. Secreted IFNc was measured by ELISA in the media of cultured HSCs isolated from
rats treated with either chlodronate-liposomes (E) or empty liposome control (F). (G) Expression of MHC class II on macrophages cultured in qHSC
conditioned media. Flow cytometric analysis of control macrophages (untreated), or macrophages incubated with control media, untreated qHSC
conditioned media, Poly(I:C) treated qHSC conditioned media or 100 ng/ml recombinant IFNc as positive control. (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0083391.g003
Figure 4. Interferon gamma and IL-6 expression are TLR3 mediated and loss of ability to induce IFNc in aHSCs is associated with
transcriptional repression by Polycomb complex. (A) WT and tlr32/2 activated mHSCs were treated with Poly(I:C) (1 mg/ml) for 8 and 24 hours;
subsequently IFNc mRNA expression was measured by qPCR. Data are normalised to GAPDH and expressed as fold induction relative to control. (B)
IL-6 mRNA expression was measured in WT and tlr32/2 activated mHSCs in response to increasing concentrations of Poly(I:C). (C) Wild type qHSCs
were treated with transcriptional inhibitors Act D (1 mM) and DRB (80 mM) for 24 hours and IL-6 mRNA expression analysed by qRT-PCR. Data are
normalised to GAPDH and expressed as fold induction relative to untreated control. (D and E) One hundred micrograms of crosslinked chromatin
from quiescent and activated rat HSC was incubated with 10 mg of anti-trimethyl and anti-dimethyl H3K27 antibody and ChIP assay performed. Data
are expressed as fold enrichment relative to IgG control. (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0083391.g004
Role of TLR3 in Quiescent Hepatic Stellate Cells
PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e83391
cultured with media supplemented with maximal dose of
recombinant IFNc (Figure 3G).
As dsRNAs and Poly(I:C) are able to induce innate immune
responses via alternative pathways from those triggered by TLR3
(e.g. RIG-1 and MDA5) we wished to confirm that the IFN and
IL-6 responses we have described can be specifically attributed to
TLR3 signalling. We therefore compared responses to Poly(I:C)
between freshly isolated, quiescent wild type and tlr32/2 HSC.
Treatment of wild type qHSC with Poly(I:C) was again associated
with a time-dependent induction of IFNc which was not detected
with tlr32/2 qHSC (Figure 4A) (2.8360.8 RLTD WT control
p = 0.048). For measurement of the IL-6 response, we performed a
detailed Poly(I:C) dose-response with aHSC, ranging from 10 ng/
ml to 25 mg/ml (Figure 4B). For wild type aHSC, IL-6 induction
was observed at 1 mg/ml (2-fold), 10 mg/ml (6-fold) and 25 mg/ml
(10-fold). By contrast a modest 3-fold induction of IL-6 transcript
was observed with the highest 25 mg/ml dose for tlr32/2 cells
which is likely to be non-specific at this very high concentration of
Poly(I:C). Abrogation of TLR3 signalling resulted in a significant,
but incomplete reduction of IL-6 mRNA expression. We cannot
exclude the possibility that MDA5 or RIG-1 may play a role in this
setting, however, it is worth noting a complete absence of any
additional IL-6 production in tlr32/2 HSCs at 1 mg/ml of
Poly(I:C) which was the concentration used throughout all other
experiments. Treatment of wild type qHSC with transcriptional
inhibitors actinomycin D and 5,6-Dichlorobenzimidazole Ribo-
side (DRB) confirmed that TLR3 mediated activation of IL-6
expression is regulated at the transcriptional level (Figure 4C). To
investigate an explanation for the inability of aHSC to mount an
IFNc response following engagement of TLR3 we employed
chromatin immunoprecipitation (ChIP) to determine if chromatin
structure is modified at the IFNc gene. Di- and tri-methylation of
lysine 27 on Histone 3 (H3K27) is associated with transcription-
ally-repressed chromatin mediated by Polycomb proteins [21].
Activated HSC acquire the repressive dimethyl-H3K27 signature
within the downstream coding region of the IFNc gene
(Figure 4D). Additionally, relative to qHSC, aHSC show
enrichment of trimethyl-H3K27 in both the upstream promoter
and downstream coding regions (Figure 4E). These data suggest
that remodelling of the HSC epigenome during their transdiffer-
entiation to a myofibroblastic phenotype includes Polycomb-
mediated silencing of the IFNc gene.
Discussion
The innate immune response of the liver is essential for the
clearance of pathogenic microbes and initiation of the hepatic
wound-healing response to liver trauma or toxic damage. TLR3 is
an important component of the innate immune system providing a
sensor for dsRNA originating from RNA viruses or leakage from
damaged host cells [22]. In liver, TLR3 is expressed on
parenchymal and non-parenchymal cells as well as infiltrating
immune cells. Activation of TLR3 signalling in the liver leads to
inflammation and injury through induction of NK cell activation
and accumulation [23].
Augmentation of mouse liver-associated natural killer activity by
biologic response modifiers occurs largely via rapid recruitment of
large granular lymphocytes from the bone marrow [24]. TLR3
activated NK cells produce IFNc which has been shown to induce
apoptosis of activated HSC and to inhibit their proliferation. This
in turn limits further progression of liver fibrosis [25,26]. TLR3 is
further involved in numerous processes within the liver, ranging
from regeneration, viral hepatitis infection as well as autoimmune
disease (reviewed in [27]).
TLR3 along with TLR4 has been implicated in the control of
HCV replication via stimulation of IFNc [28,29]. Furthermore,
TLR3 signalling has been implicated as an important controller of
CD8+ T cell infiltration via the induction of IFNc and chemokines
such as CXCL9 [28]. This latter pathway has been proposed to
promote liver damage and possibly facilitate the development of
autoimmune hepatitis [30]. These observations suggest important
but complex functions for TLR3 in liver homeostasis and
immunity, as such it will be critical to define the cellular events
that regulate TLR3 responses if TLR3 signalling is to be targeted
therapeutically.
Non-parencymal liver cells that have previously been shown to
express TLR3 in the liver include resident KC and liver sinusoidal
endothelial cells (LSECs) [29,31]. Here, we provide evidence that
rodent HSC express TLR3 in both their quiescent and activated
phenotypes. Of note our data are in contrast to a recently
published study which reported an absence of TLR3 in quiescent
HSC. The reasons for this discrepancy are unclear but may relate
to differences in isolation procedures, or that while we mainly
focus our studies on rat HSC, the previous study utilised mouse
HSC [32]. Importantly we have also demonstrated an unexpected
innate immune function for qHSC, since they can express type I
and type II interferons in response to Poly(I:C) treatment and in a
TLR3-dependent manner. Interestingly this property of qHSC is
lost during transdifferentiation to their activated phenotype,
despite the cells retaining TLR3 expression and ability to elevate
their production of IL-6 in response to Poly(I:C) treatment. By
focusing on the IFNc gene we were able to show that aHSC
acquire transcriptionally repressive chromatin modifications that
may in part explain loss of IFNc production (Figure 4D and E).
Presumably this loss of IFNc response protects aHSC from the
previously documented anti-fibrogenic and pro-apoptotic actions
of IFNc, which if produced in an autocrine manner would act to
suppress their fibrogenic function [33].
Recent reports suggest that the HSC phenotype is more plastic
than previously thought, particularly in the context of liver injuries
that may periodically resolve and recur. It is proposed that aHSC
that avoid apoptosis during resolution of fibrogenesis can revert to
a more quiescent phenotype (iHSC), although in a state where
they are primed to activate more efficiently than naive qHSC
[34,35]. Given that iHSC may be within microenvironments
where liver damage is not fully resolved, it would be interesting to
determine if their phenotype reversion recovers their ability to
express IFNs in response to dsRNA. Chronic production of IFNs
by these cells in significant numbers and in the context of recurring
liver damage may promote immune dysfunction of relevance to
acute and chronic pathologies.
In summary, we have discovered an unexpected role for TLR3
in qHSC as a stimulator of type I and type II interferon expression
in response to Poly(I:C) treatment. We propose that prior to
activation, qHSC may contribute to the induction of the hepatic
innate immune response to injury or infection. Further investiga-
tion of the function of TLR3 on qHSC may therefore lead to
strategies for modulating the recruitment and activation of innate
immune cells during acute viral infections and drug-induced liver
injuries.
Supporting Information
Figure S1 HSCs were isolated from control, acute CCl4
treated rats (single injection), or chronic CCl4 treated
rats (4 weeks twice weekly injections); cells were seeded
onto plates and treated with Poly(I:C) (1 mg/ml) for up to
24 h. We found no change in the induction of CTGF, IL10,
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MCP1, and RANTES (CCL5) in transitionary or activated HSCs
compared with control.
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